請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15758完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 闕玲玲(Ling-Ling Chueh) | |
| dc.contributor.author | Wan-Ting Tsai | en |
| dc.contributor.author | 蔡婉婷 | zh_TW |
| dc.date.accessioned | 2021-06-07T17:51:30Z | - |
| dc.date.copyright | 2012-10-12 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-09-17 | |
| dc.identifier.citation | 1. Jacob H (1914) Therapeutische, kasuistische und statistische Mit-teilungen aus der Klinik fur kleine Haustiere an der Reichstierarzneischule in Utrecht (Holland). Zschr Tiermed 18: 193.
2. Zook BC, King NW, Robison RL, Mccombs HL (1968) Ultrastructural Evidence for Viral Etiology of Feline Infectious Peritonitis. Pathologia Veterinaria 5: 91. 3. Gorbalenya AE, Snijder EJ, Spaan WJ (2004) Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol 78: 7863-7866. 4. Woo PC, Wang M, Lau SK, Xu H, Poon RW, et al. (2007) Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol 81: 1574-1585. 5. Horzinek MC, Lutz H, Pedersen NC (1982) Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses. Infect Immun 37: 1148-1155. 6. Ballesteros ML, Sanchez CM, Enjuanes L (1997) Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. Virology 227: 378-388. 7. Xu Y, Liu Y, Lou Z, Qin L, Li X, et al. (2004) Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem 279: 30514-30522. 8. Kielian M, Rey FA (2006) Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4: 67-76. 9. Liu S, Zhang X, Wang Y, Li C, Han Z, et al. (2009) Molecular characterization and pathogenicity of infectious bronchitis coronaviruses: complicated evolution and epidemiology in china caused by cocirculation of multiple types of infectious bronchitis coronaviruses. Intervirology 52: 223-234. 10. Regan AD, Shraybman R, Cohen RD, Whittaker GR (2008) Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet Microbiol 132: 235-248. 11. Chang HW, Egberink HF, Halpin R, Spiro DJ, Rottier PJ (2012) Spike protein fusion Peptide and feline coronavirus virulence. Emerg Infect Dis 18: 1089-1095. 12. Terada Y, Shiozaki Y, Shimoda H, Mahmoud HY, Noguchi K, et al. (2012) Feline infectious peritonitis virus with a large deletion in the 5' terminal region of spike gene retains its virulence for cats. J Gen Virol. 13. Horsburgh BC, Brierley I, Brown TD (1992) Analysis of a 9.6 kb sequence from the 3' end of canine coronavirus genomic RNA. J Gen Virol 73 ( Pt 11): 2849-2862. 14. Chang HW, de Groot RJ, Egberink HF, Rottier PJ (2010) Feline infectious peritonitis: insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the viral 3c gene. J Gen Virol 91: 415-420. 15. Vennema H, Poland A, Foley J, Pedersen NC (1998) Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 243: 150-157. 16. Spaan W, Cavanagh D, Horzinek MC (1988) Coronaviruses: structure and genome expression. J Gen Virol 69 ( Pt 12): 2939-2952. 17. De Groot RJ, Andeweg AC, Horzinek MC, Spaan WJ (1988) Sequence analysis of the 3'-end of the feline coronavirus FIPV 79-1146 genome: comparison with the genome of porcine coronavirus TGEV reveals large insertions. Virology 167: 370-376. 18. Vennema H, Rossen JW, Wesseling J, Horzinek MC, Rottier PJ (1992) Genomic organization and expression of the 3' end of the canine and feline enteric coronaviruses. Virology 191: 134-140. 19. Haijema BJ, Volders H, Rottier PJ (2004) Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 78: 3863-3871. 20. Herrewegh AA, Vennema H, Horzinek MC, Rottier PJ, de Groot RJ (1995) The molecular genetics of feline coronaviruses: comparative sequence analysis of the ORF7a/7b transcription unit of different biotypes. Virology 212: 622-631. 21. Lin CN, Su BL, Huang HP, Lee JJ, Hsieh MW, et al. (2009) Field strain feline coronaviruses with small deletions in ORF7b associated with both enteric infection and feline infectious peritonitis. J Feline Med Surg 11: 413-419. 22. Hohdatsu T, Yamato H, Ohkawa T, Kaneko M, Motokawa K, et al. (2003) Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP. Vet Microbiol 97: 31-44. 23. Herrewegh AA, Smeenk I, Horzinek MC, Rottier PJ, de Groot RJ (1998) Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol 72: 4508-4514. 24. Hohdatsu T, Izumiya Y, Yokoyama Y, Kida K, Koyama H (1998) Differences in virus receptor for type I and type II feline infectious peritonitis virus. Arch Virol 143: 839-850. 25. Regan AD, Whittaker GR (2008) Utilization of DC-SIGN for entry of feline coronaviruses into host cells. J Virol 82: 11992-11996. 26. Mochizuki M, Mitsutake Y, Miyanohara Y, Higashihara T, Shimizu T, et al. (1997) Antigenic and plaque variations of serotype II feline infectious peritonitis coronaviruses. J Vet Med Sci 59: 253-258. 27. Addie DD, Schaap IA, Nicolson L, Jarrett O (2003) Persistence and transmission of natural type I feline coronavirus infection. J Gen Virol 84: 2735-2744. 28. Benetka V, Kubber-Heiss A, Kolodziejek J, Nowotny N, Hofmann-Parisot M, et al. (2004) Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet Microbiol 99: 31-42. 29. Duarte A, Veiga I, Tavares L (2009) Genetic diversity and phylogenetic analysis of Feline Coronavirus sequences from Portugal. Vet Microbiol 138: 163-168. 30. Hohdatsu T, Okada S, Ishizuka Y, Yamada H, Koyama H (1992) The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 54: 557-562. 31. Kummrow M, Meli ML, Haessig M, Goenczi E, Poland A, et al. (2005) Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol 12: 1209-1215. 32. Lin CN, Su BL, Wang CH, Hsieh MW, Chueh TJ, et al. (2009) Genetic diversity and correlation with feline infectious peritonitis of feline coronavirus type I and II: a 5-year study in Taiwan. Vet Microbiol 136: 233-239. 33. Pedersen NC, Black JW (1983) Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 44: 229-234. 34. Shiba N, Maeda K, Kato H, Mochizuki M, Iwata H (2007) Differentiation of feline coronavirus type I and II infections by virus neutralization test. Vet Microbiol 124: 348-352. 35. An DJ, Jeoung HY, Jeong W, Park JY, Lee MH, et al. (2011) Prevalence of Korean cats with natural feline coronavirus infections. Virology Journal 8. 36. Horzinek MC, Osterhaus AD (1979) Feline infectious peritonitis: a worldwide serosurvey. Am J Vet Res 40: 1487-1492. 37. Sparkes AH, Gruffydd-Jones TJ, Harbour DA (1992) Feline coronavirus antibodies in UK cats. Vet Rec 131: 223-224. 38. Addie DD, Jarrett O (1992) A study of naturally occurring feline coronavirus infections in kittens. Vet Rec 130: 133-137. 39. Addie DD, Toth S, Murray GD, Jarrett O (1995) Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. Am J Vet Res 56: 429-434. 40. Foley JE, Poland A, Carlson J, Pedersen NC (1997) Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. J Am Vet Med Assoc 210: 1313-1318. 41. Rohrbach BW, Legendre AM, Baldwin CA, Lein DH, Reed WM, et al. (2001) Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. J Am Vet Med Assoc 218: 1111-1115. 42. Norris JM, Bosward KL, White JD, Baral RM, Catt MJ, et al. (2005) Clinicopathological findings associated with feline infectious peritonitis in Sydney, Australia: 42 cases (1990-2002). Aust Vet J 83: 666-673. 43. Pesteanu-Somogyi LD, Radzai C, Pressler BM (2006) Prevalence of feline infectious peritonitis in specific cat breeds. J Feline Med Surg 8: 1-5. 44. Hartmann K (2005) Feline infectious peritonitis. Vet Clin North Am Small Anim Pract 35: 39-79, vi. 45. Rohrer JE (1993) Small area analysis: descriptive epidemiology in health services research. Clin Perform Qual Health Care 1: 35-42. 46. Addie DD, Jarrett O (2001) Use of a reverse-transcriptase polymerase chain reaction for monitoring the shedding of feline coronavirus by healthy cats. Vet Rec 148: 649-653. 47. Pedersen NC, Allen CE, Lyons LA (2008) Pathogenesis of feline enteric coronavirus infection. J Feline Med Surg 10: 529-541. 48. Stoddart ME, Gaskell RM, Harbour DA, Gaskell CJ (1988) Virus shedding and immune responses in cats inoculated with cell culture-adapted feline infectious peritonitis virus. Vet Microbiol 16: 145-158. 49. Herrewegh AA, Mahler M, Hedrich HJ, Haagmans BL, Egberink HF, et al. (1997) Persistence and evolution of feline coronavirus in a closed cat-breeding colony. Virology 234: 349-363. 50. Pedersen NC, Boyle JF, Floyd K, Fudge A, Barker J (1981) An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res 42: 368-377. 51. Can-Sahna K, Soydal Ataseven V, Pinar D, Oguzoglu TC (2007) The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. J Feline Med Surg 9: 369-372. 52. Pedersen NC (1987) Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 218: 529-550. 53. Pedersen NC (2009) A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 11: 225-258. 54. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ (2005) Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J Virol 79: 1036-1044. 55. Pedersen NC (1995) An Overview of Feline Enteric Coronavirus and Infectious Peritonitis Virus-Infections. Feline Practice 23: 7-20. 56. Cannon MJ, Silkstone MA, Kipar AM (2005) Cutaneous lesions associated with coronavirus-induced vasculitis in a cat with feline infectious peritonitis and concurrent feline immunodeficiency virus infection. J Feline Med Surg 7: 233-236. 57. Trotman TK, Mauldin E, Hoffmann V, Del Piero F, Hess RS (2007) Skin fragility syndrome in a cat with feline infectious peritonitis and hepatic lipidosis. Vet Dermatol 18: 365-369. 58. Declercq J, De Bosschere H, Schwarzkopf I, Declercq L (2008) Papular cutaneous lesions in a cat associated with feline infectious peritonitis. Vet Dermatol 19: 255-258. 59. Rohrer C, Suter PF, Lutz H (1993) The Diagnostic of the Feline Infectious Peritonitis (Fip) - Retrospective and Prospective Investigations. Kleintierpraxis 38: 379-389. 60. Herrewegh AA, de Groot RJ, Cepica A, Egberink HF, Horzinek MC, et al. (1995) Detection of feline coronavirus RNA in feces, tissues, and body fluids of naturally infected cats by reverse transcriptase PCR. J Clin Microbiol 33: 684-689. 61. Ward BC, Pederson N (1969) Infectious peritonitis in cats. J Am Vet Med Assoc 154: 26-35. 62. Robison RL, Holzworth J, Gilmore CE (1971) Naturally occurring feline infectious peritonitis: signs and clinical diagnosis. J Am Vet Med Assoc 158: Suppl 2:981-986. 63. Sparkes AH, Gruffyddjones TJ, Harbour DA (1994) An Appraisal of the Value of Laboratory Tests in the Diagnosis of Feline Infectious Peritonitis. J Am Anim Hosp Assoc 30: 345-350. 64. Hartmann K, Binder C, Hirschberger J, Cole D, Reinacher M, et al. (2003) Comparison of different tests to diagnose feline infectious peritonitis. J Vet Intern Med 17: 781-790. 65. Sparkes AH, Gruffydd-Jones TJ, Harbour DA (1991) Feline infectious peritonitis: a review of clinicopathological changes in 65 cases, and a critical assessment of their diagnostic value. Vet Rec 129: 209-212. 66. Paltrinieri S, Cammarata MP, Cammarata G, Comazzi S (1998) Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis. Vet Immunol Immunopathol 65: 205-220. 67. Gerber JD, Ingersoll JD, Gast AM, Christianson KK, Selzer NL, et al. (1990) Protection against feline infectious peritonitis by intranasal inoculation of a temperature-sensitive FIPV vaccine. Vaccine 8: 536-542. 68. Tsai HY, Chueh LL, Lin CN, Su BL (2011) Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. J Feline Med Surg 13: 74-80. 69. Weiss RC, Cox NR, Oostrom-Ram T (1990) Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res 51: 726-733. 70. Weiss RC, Toivio-Kinnucan M (1988) Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. Am J Vet Res 49: 1329-1335. 71. Ritz S, Egberink H, Hartmann K (2007) Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med 21: 1193-1197. 72. Weiss RC, Oostrom-Ram T (1989) Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 20: 255-265. 73. Hsieh LE, Lin CN, Su BL, Jan TR, Chen CM, et al. (2010) Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res 88: 25-30. 74. Ishida Y, Shibanai A, Tanaka S, Uchida K, Mochizuki M (2004) Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med Surg 6: 107-109. 75. Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, et al. (2012) Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res 43: 41. 76. Legendre AM, Bartges JW (2009) Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg 11: 624-626. 77. Hartmann K, Ritz S (2008) Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol 123: 172-175. 78. Barlough JE, Johnson-Lussenburg CM, Stoddart CA, Jacobson RH, Scott FW (1985) Experimental inoculation of cats with human coronavirus 229E and subsequent challenge with feline infectious peritonitis virus. Can J Comp Med 49: 303-307. 79. Barlough JE, Stoddart CA, Sorresso GP, Jacobson RH, Scott FW (1984) Experimental inoculation of cats with canine coronavirus and subsequent challenge with feline infectious peritonitis virus. Lab Anim Sci 34: 592-597. 80. McArdle F, Bennett M, Gaskell RM, Tennant B, Kelly DF, et al. (1992) Induction and enhancement of feline infectious peritonitis by canine coronavirus. Am J Vet Res 53: 1500-1506. 81. Traynor ME, Schlapfer WT, Woodson PB, Barondes SH (1979) Cross-tolerance to effect of ethanol and temperature in Aplysia: preliminary observations. Alcohol Clin Exp Res 3: 57-59. 82. Weiss RC, Scott FW (1981) Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 4: 175-189. 83. Jacobsegeels HEL, Daha MR, Horzinek MC (1982) Antibody, Immune-Complexes, and Complement Activity Fluctuations in Kittens with Experimentally Induced Feline Infectious Peritonitis. Am J Vet Res 43: 666-670. 84. Stoddart CA, Scott FW (1989) Intrinsic resistance of feline peritoneal macrophages to coronavirus infection correlates with in vivo virulence. J Virol 63: 436-440. 85. Christianson KK, Ingersoll JD, Landon RM, Pfeiffer NE, Gerber JD (1989) Characterization of a temperature sensitive feline infectious peritonitis coronavirus. Arch Virol 109: 185-196. 86. Fehr D, Holznagel E, Bolla S, Hauser B, Herrewegh AA, et al. (1997) Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine 15: 1101-1109. 87. Reeves NC, Pollock RV, Thurber ET (1992) Long-term follow-up study of cats vaccinated with a temperature-sensitive feline infectious peritonitis vaccine. Cornell Vet 82: 117-123. 88. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801-8811. 89. Porotto M, Yokoyama CC, Palermo LM, Mungall B, Aljofan M, et al. (2010) Viral entry inhibitors targeted to the membrane site of action. J Virol 84: 6760-6768. 90. Medinas RJ, Lambert DM, Tompkins WA (2002) C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J Virol 76: 9079-9086. 91. Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, et al. (2011) Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem 286: 15854-15861. 92. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, et al. (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 93: 2186-2191. 93. Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, et al. (2009) Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res 81: 82-87. 94. Liu SW, Xiao GF, Chen YB, He YX, Niu JK, et al. (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363: 938-947. 95. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774. 96. Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884-888. 97. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307. 98. Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365: 113. 99. Oldfield V, Keating GM, Plosker G (2005) Enfuvirtide: a review of its use in the management of HIV infection. Drugs 65: 1139-1160. 100. Lin CN, Su BL, Wu CW, Hsieh LN, Chueh LL (2009) Isolation and identification of a novel feline coronavirus from a kitten with naturally occurring feline infectious peritonitis in Taiwan. Taiwan Vet J 35: 145. 101. Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, et al. (2009) FELINE INFECTIOUS PERITONITIS ABCD guidelines on prevention and management. J Feline Med Surg 11: 594-604. 102. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, et al. (2000) Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 74: 10194-10201. 103. Duquerroy S, Vigouroux A, Rottier PJ, Rey FA, Bosch BJ (2005) Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein. Virology 335: 276-285. 104. Supekar VM, Bruckmann C, Ingallinella P, Bianchi E, Pessi A, et al. (2004) Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci U S A 101: 17958-17963. 105. Lau SY, Taneja AK, Hodges RS (1984) Synthesis of a model protein of defined secondary and quaternary structure. Effect of chain length on the stabilization and formation of two-stranded alpha-helical coiled-coils. J Biol Chem 259: 13253-13261. 106. Rapaport D, Ovadia M, Shai Y (1995) A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J 14: 5524-5531. 107. Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, et al. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106: 5801-5806. 108. Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4: 1011-1033. 109. van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Verheije MH, et al. (2007) The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother 60: 741-749. 110. Kipar A, Kohler K, Leukert W, Reinacher M (2001) A comparison of lymphatic tissues from cats with spontaneous feline infectious peritonitis (FIP), cats with FIP virus infection but no FIP, and cats with no infection. J Comp Pathol 125: 182-191. 111. Haagmans BL, Egberink HF, Horzinek MC (1996) Apoptosis and T-cell depletion during feline infectious peritonitis. J Virol 70: 8977-8983. 112. Ward JM, Gribble DH, Dungworth DL (1974) Feline infectious peritonitis: experimental evidence for its multiphasic nature. Am J Vet Res 35: 1271-1275. 113. Weiss RC, Cox NR, Boudreaux MK (1993) Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 16: 301-316. 114. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972. 115. Ball RA, Kinchelow T (2003) Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826-831. 116. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, et al. (2002) The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 18: 685-693. 117. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15758 | - |
| dc.description.abstract | 貓傳染性腹膜炎 (Feline infectious peritonitis, FIP) 為貓冠狀病毒 (Feline coronavirus, FCoV) 所引起之一免疫媒介高度致死性疾病，目前尚無有效之疫苗及治療方法。本研究利用以severe acute respiratory syndrome coronavirus (SARS-CoV) 及FCoV之棘蛋白(spike protein, S) heptad repeat 2 (HR2) 序列為基礎所合成之胜肽，藉由抑制FCoV感染之融合效應，測試其抑制病毒複製之效力。結果顯示在20 μM濃度下，SARS-CoV HR胜肽具33% 至55% 之抑制病毒效力，而FCoV-HR 胜肽之抑制病毒效力則可達到72% 至97%。此結果表示相較於SARS-CoV HR 胜肽，FCoV HR 胜肽對於FCoV之抑制更具特異性。進一步探討HR 胜肽與其他已知具抗FCoV複製藥物之加乘作用 (Synergistic antiviral effect)，將SARS-CoV HR胜肽與nelfinavir、Galanthus nivalis agglutinin (GNA) 合併未出現加乘作用，而與人源Interferon-α (IFN-α) 合併，則發現以20 μM FCoV HR胜肽與不同濃度之IFN-α合併後皆出現加乘抗病毒效應。探討此FCoV HR胜肽之抑制機制發現其主要是藉由干擾病毒與標的細胞之融合，進而抑制病毒之複製。總結本實驗之結果，FCoV HR 胜肽為一具有潛力可應用於FIP臨床預防及治療之藥物。 | zh_TW |
| dc.description.abstract | Feline infectious peritonitis (FIP) is an immune-mediated disease with high mortality rate in felids caused by feline coronavirus (FCoV). At present, no effective vaccine or treatments are available for FIP. We carried out fusion inhibition assay to analyze the designed peptides based on spike protein (S) heptad repeat 2 (HR2) sequences of severe acute respiratory syndrome coronavirus (SARS-CoV) and FCoV. The results showed the inhibition percentages of FCoV replication for 20 μM of SARS-CoV and FCoV peptides were 31% to 55% and 72% to 97%, respectively. This indicates that the peptides derived from FCoV are more specific than from SARS-CoV. The effective FCoV-derived peptides were further tested for their synergistic antiviral effect with other known anti-FCoV agents, i.e. Galanthus nivalis agglutinin 會, nelfinavir and human interferon-α (IFN-α). When 20 μM of FCoV HR peptide was combined with different concentrations of IFN-α, a significant synergistic anti-FCoV effect can be observed, however not with GNA and nelfinavir. Investigation of the inhibition mechanism for FCoV-derived HR peptide revealed that the peptide interferes with virus-cell fusion thus leading to a reduction in viral replication. Taken together, the peptides derived from FCoV have the potential to be used as a therapeutic agent in the prevention and treatment of FIP. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T17:51:30Z (GMT). No. of bitstreams: 1 ntu-101-R99629029-1.pdf: 1249901 bytes, checksum: 66fe1d12f668cafd7d98a60f816b04fa (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
中文摘要 ii ABSTRACT iii 目錄 iv 表次 vii 圖次 viii 第一章、 文獻探討 1 第一節、歷史背景 1 第二節、 病毒分類 1 第三節、 基因體特性 2 第四節、 貓冠狀病毒之分型 5 第五節、 貓冠狀病毒之感染與疾病 5 一、 宿主與流行病 5 二、 傳染途徑及排毒模式 6 三、 致病機制 6 四、 臨床症狀 7 五、 診斷 8 六、 治療 9 七、 預防與控制 11 第六節、 抗病毒胜肽 12 第二章、 序言 13 第三章、 材料與方法 15 第一節、 病毒與細胞 15 第二節、 抗病毒胜肽 15 一、 SARS-CoV S protein HR2抗病毒胜肽 15 二、 FCoV S protein HR2抗病毒胜肽 15 第三節、 細胞活性試驗 15 第四節、 抗病毒胜肽效力之體外評估 16 一、 篩選具抗病毒效應之胜肽 16 二、 藥物合併效力試驗 17 三、 FCoV S protein HR胜肽抑制FCoV複製機制之探討 18 四、 統計分析 18 第四章、 結果 19 第五章、 討論 23 附表 29 附圖 31 參考文獻 39 | |
| dc.language.iso | zh-TW | |
| dc.title | 抗病毒胜肽抑制貓冠狀病毒複製之評估 | zh_TW |
| dc.title | Evaluation of the Inhibitory Effect of Anti-Viral Peptides against Feline Coronavirus | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 劉薏蓉(I-Jung Liu) | |
| dc.contributor.oralexamcommittee | 項千芸(Chien-Yun Hsiang),張淑媛(Shu-Yuan Chang),林昭男(Chao-Nan Lin) | |
| dc.subject.keyword | 貓冠狀病毒,貓傳染性腹膜炎,抗病毒藥物,胜肽, | zh_TW |
| dc.subject.keyword | FCoV,FIP,antiviral agent,peptide, | en |
| dc.relation.page | 52 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2012-09-18 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 目前未授權公開取用 | 1.22 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。